The Complete Oncology Diagnosis Guide: Step by Step

You just found out you have cancer. Or that there is a serious suspicion. The world has stopped.

I know what you are going through. I have been there.

In moments like these, the instinct is to do anything –immediately. To accept the first plan someone proposes. To rush into treatment. But here is what I learned the hard way: the most important thing you can do right now is to reach a complete and accurate diagnosis before making any treatment decision.

This guide shows you exactly what steps to follow, in what order, and –just as importantly –what to avoid. It is the roadmap I wish I had.

Why the order of steps matters

An oncology diagnosis is not a single test. It is a protocol –a series of investigations that, done in the correct order, give you the full picture of your disease. Each step depends on the one before it.

In a specialized oncology center, this protocol can take 10 days. In a fragmented system, without coordination, it can take 8 weeks or more –not because the tests themselves take longer, but because nobody is coordinating them efficiently.

The difference is not just about comfort. The difference can be between an optimal treatment and a suboptimal one. An incomplete diagnosis leads to incomplete decisions.

Step 1: Whole-body PET-CT –see the full picture FIRST

The correct first step is to see the full extent of the disease. Not a simple CT, not an ultrasound. A whole-body PET-CT (from head to knee or below).

What is PET-CT?

PET-CT combines two technologies: PET (Positron Emission Tomography) shows metabolic activity –meaning where cells are consuming energy more than normal (the sign of an active tumor). CT (Computed Tomography) shows anatomy –the shape, size, and exact location.

Together, PET-CT shows you what is there and how active it is, across your entire body, in a single investigation.

Why PET-CT BEFORE biopsy?

• It shows whether the disease is localized or has spread (metastases)
• It guides the biopsy – the doctor knows exactly where to sample, from the area with the strongest tumor activity. Without PET-CT, you risk the biopsy being taken from an inactive zone, and the result being inconclusive or inaccurate.
• It can completely change the approach: if metastases are present, the treatment plan is different
• PET-CT changes staging in 19-35% of cases compared to simple CT

Equipment quality matters

Not all PET-CTs are equal. State-of-the-art machines offer:

• Lower radiation doses (important, especially if you will need multiple scans)
• Higher resolution –detecting smaller lesions
• AI-assisted interpretation in some centers

Ask what PET-CT model the center uses and when it was installed. Newer, latest-generation machines make a difference.

Step 2: Biopsy –the material everything is built on

A biopsy is the procedure through which a piece of the tumor is collected to be analyzed under a microscope. Without a biopsy, there is no definitive diagnosis.

Types of biopsy

• Fine needle aspiration (FNA): Fast, minimally invasive. Used for thyroid, superficial lymph nodes. But it may collect too little material.
• Core needle biopsy: Collects a cylinder of tissue. Preferred for most solid tumors. Sensitivity 85-100%.
• CT-guided or ultrasound-guided biopsy: The needle is guided by imaging to the tumor. Essential for deep tumors (lung, liver, bone).
• Surgical biopsy: When other methods are not possible or sufficient.

How long do results take?

• Basic histopathology report: 3-7 business days in a good center
• With immunohistochemistry (IHC): another 1-2 days
• In a specialized oncology center, the biopsy result can come in 3 days

Ideally, choose a center that can guarantee fast turnaround times. If you are told the result takes 2-3 weeks, ask whether faster options exist – including sending the sample to another lab or having it evaluated at a specialized center.

Request fresh frozen tissue –not just FFPE

By default, your biopsy tissue will be preserved in formaldehyde and embedded in paraffin (called FFPE). This is standard and sufficient for most tests. But some advanced options – cancer vaccines, organoid drug testing, high-quality RNA sequencing – require fresh frozen tissue stored at -80 degrees Celsius.

You cannot go back and freeze tissue after it has already been fixed in formaldehyde. The decision must be made before the biopsy, not after.

Ask the interventional radiologist or surgeon: “Can you also store some tissue cores fresh frozen at -80 degrees for future research and advanced testing?” If the center cannot do this, ask whether they can send cores to a biobank that can.

Ideally, request 4-8 biopsy cores distributed between:

• Pathology (diagnosis – mandatory, always done)
• Molecular testing (NGS, WES, RNA-seq)
• Fresh frozen biobank at -80 degrees (for future options: vaccines, organoids, retesting)

This one request, made at the right moment, can open treatment doors that do not yet exist today.

Step 3: Molecular and genetic testing –the most overlooked step

This is probably the most important step that nobody talks about enough. Molecular tests analyze the DNA of your tumor and identify the specific mutations driving it. These mutations determine which treatment works and which does not.

Why does it change everything?

Modern oncology has evolved enormously. Today there are targeted therapies – drugs designed to specifically attack certain genetic mutations in your tumor. These treatments are often more effective and better tolerated than traditional chemotherapy.

But to receive the right treatment, you need to know what mutation you have.

Two patients with “lung cancer” can have completely different diseases at the molecular level. One has an EGFR mutation – and there is a targeted drug that works remarkably well. The other has a KRAS G12C mutation – and a different drug works. Without molecular testing, the doctor does not know which treatment is right for YOU.

Not just for lung cancer

This is a common misconception. Molecular testing is the standard of care (meaning mandatory according to international guidelines) for most advanced cancers:

For a concrete example, read our complete guide to RET fusion-positive lung cancer – a molecular subtype with a highly effective targeted treatment.

“Agnostic” biomarkers –valid for ANY cancer

Regardless of your cancer type, there are biomarkers that can unlock treatment options for any solid tumor:

• MSI-H/dMMR –responds to immunotherapy (pembrolizumab)
• NTRK fusions –responds to larotrectinib or entrectinib
• TMB-H (high tumor mutational burden) –responds to immunotherapy
• BRAF V600E –combination dabrafenib + trametinib

These should be tested regardless of what cancer you have.

Two types of tests: somatic and germline

• Somatic testing (of the tumor): Analyzes mutations acquired by your tumor. Done from biopsy tissue or from blood (liquid biopsy). Guides treatment.
• Germline testing (hereditary): Analyzes inherited mutations, present since birth. Done from a blood sample. Important for you AND for your family (cancer risk in relatives).

They are not interchangeable. You may need both.

How long do they take?

• Rapid panel (subset of mutations): 3 days in specialized centers
• Full NGS panel: 7-14 days in a good lab
• Outsourced: can take 2-4 weeks

Beyond standard panels: WES, WGS and RNA-seq

A standard NGS panel tests 50-500 genes. This is usually sufficient – but not always. For rare cancers, unusual molecular subtypes, or when the standard panel finds nothing actionable, more comprehensive options exist:

• Whole Exome Sequencing (WES): Tests all protein-coding genes (~20,000). Identifies co-mutations, neoantigen candidates for vaccines, and DNA repair defects (BRCA, FANCL, ATM)
• Whole Genome Sequencing (WGS): Tests the entire genome, including non-coding regions. The most comprehensive option – 73-89% of patients receive actionable findings. Non-profit and academic programs exist in some EU countries: Hartwig Medical Foundation OncoAct (Netherlands, NSCLC explicitly covered) and NCT MASTER (Heidelberg, Germany – WGS + RNA-seq + methylome). Access depends on your country – these programs are typically reimbursed for patients in their home country’s healthcare system, but international patients usually need a cross-border referral, an S2 form (EU Cross-Border Healthcare Directive), or private payment. Ask your oncologist whether your country has a pathway to these programs or whether they accept international referrals
• RNA-seq: Shows which genes are actually active in your tumor. Can detect gene fusions, bypass resistance mechanisms, and transcriptional changes invisible to DNA-only testing

These advanced tests are not always reimbursed by standard health insurance. Ask your oncologist whether they are covered or whether academic programs (often free) accept your case.

Step 3b: AI-assisted pathology –preserving precious tissue

A new generation of AI tools can predict biomarkers directly from standard biopsy slides (H&E staining), before cutting additional tissue for immunohistochemistry. This matters because biopsy tissue is limited – every additional test consumes irreplaceable material.

Validated platforms:

• HEX (Stanford, Nature Medicine 2026) – predicts 40 proteins and immune phenotype from standard H&E slides. Open-source and free
• Paige Predict (Tempus, commercial since January 2026) – predicts 123+ biomarkers from H&E

Not all centers have adopted these tools yet. But if your biopsy is small and tissue is limited, ask: “Can AI-assisted pathology help prioritize which additional tests to run, to conserve tissue?”

Step 3c: Liquid biopsy –diagnosis and monitoring from blood

A liquid biopsy (ctDNA test) detects tumor DNA fragments circulating in your blood. It requires only a blood draw – no needle in the tumor.

When it helps at diagnosis:

• When the tumor is in a location difficult to biopsy (deep lung, brain, bone)
• When the biopsy yielded insufficient tissue for molecular testing
• As a complement to tissue biopsy – liquid biopsy can detect mutations the tissue sample missed, and vice versa

When it helps during treatment:

• Detects resistance mutations 3-6 months before imaging shows progression
• Confirms treatment response at the molecular level (ctDNA clearance at week 8 is the strongest predictor of outcome)
• Monitors for minimal residual disease after local treatment (surgery, radiation, ablation)

Available platforms: FoundationOne Liquid CDx (300+ genes, available through partner labs in many countries including Romania), Guardant360 CDx (74 genes), and ultra-sensitive personalized platforms like Signatera and Haystack MRD for ongoing monitoring.

Step 4: Complete staging –leave nothing to chance

In addition to the initial PET-CT, some cancers require additional staging investigations:

Brain MRI

Mandatory for:

• Lung cancer –high risk of brain metastases
• Melanoma –high risk of brain metastases
• HER2+ breast cancer –increased risk

PET-CT does not “see” the brain well because of its naturally high metabolic activity. Brain MRI is the correct investigation.

Other staging investigations

• Bone scintigraphy: for prostate cancer, breast cancer (when bone metastases are suspected)
• Pelvic MRI: for pelvic cancers (rectal, cervical, prostate)

Ask your oncologist: “Is the staging complete? Do I also need a brain MRI?”

Step 5: Tumor board –doctors who talk to each other

The tumor board (also called a multidisciplinary team meeting) is the session where all involved specialists review your case and jointly decide the treatment plan.

Who participates?

• Medical oncologist –the specialist in systemic treatments (chemotherapy, targeted therapy, immunotherapy)
• Surgical oncologist –evaluates whether and when surgery is indicated
• Radiation oncologist –evaluates whether radiation therapy is indicated
• Pathologist –the one who read the biopsy, can review the diagnosis
• Radiologist –reviews the imaging live
• Clinical trials coordinator –checks whether you are eligible for clinical studies
• Plus: geneticist, nutritionist, palliative care specialist, psychologist, as needed

Why does it matter so much?

The numbers speak for themselves:

• 40% of cases presented at tumor board have the treatment plan modified
• 29-45% of cases have diagnostic changes (the pathologist or radiologist discovers something new)
• In neuro-oncology: 59% of cases have clinical management changes
• Studies show significant reductions in mortality risk for patients discussed at tumor board

Not all tumor boards are equal

• Daily: top specialized oncology centers have daily tumor boards. Your case is discussed quickly, without weeks of delay.
• Weekly: many large hospitals have tumor board once a week. Acceptable, but can add days of waiting.
• Nonexistent or superficial: some centers do not have a real tumor board. The decision is made by a single doctor. This is a red flag.

Integrated information system

In a good center, all doctors on the board have access to a single digital record –imaging, pathology, lab results, everything. There is no more “I have not seen the colleague’s result” or “you need to bring the file from another hospital.”

Step 5b: Free AI tools for genomic interpretation

When your molecular testing results arrive, several free, clinically validated platforms can help you and your oncologist interpret them:

• OncoKB (Memorial Sloan Kettering) – 8,000+ alterations classified by actionability level (FDA-approved, clinical evidence, investigational). Free for clinical use
• CIViC (Washington University) – crowd-curated clinical evidence database linking mutations to treatments. Open access
• ClinicalTrials.gov – search your specific mutations to find open clinical trials worldwide

These tools do not replace your oncologist’s judgment. They complement it by ensuring no actionable finding is overlooked – especially for rare mutations where even experienced oncologists may not be aware of every option.

Step 6: Second opinion –it is not optional, it is responsible

Asking for a second medical opinion is not an insult to your doctor. It is a responsible step that any good doctor respects.

When is it necessary?

• Always for rare cancers or unusual molecular subtypes
• When the proposed treatment plan does not seem clearly explained to you
• When you did not have a tumor board
• When something feels off –trust your instincts

How to ask without feeling awkward?

Simply say: “I want to make sure we are doing the best possible thing. I would like a second opinion at another center.” A good doctor will not be offended. If they are offended, that is itself a signal.

Where it matters to go: specialized oncology centers

Not all hospitals are equal when it comes to oncology diagnosis. A specialized oncology center makes the difference through: state-of-the-art equipment, daily tumor board, rapid molecular testing, and an integrated system where all doctors see all the information.

Real-world experience: Anadolu Medical Center, Istanbul

A patient with lung cancer had the following experience at Anadolu Medical Center:

• PET-CT as the first step – done immediately, with state-of-the-art equipment (low doses, high resolution, results in 24 hours)
• CT-guided biopsy – from the area with the highest tumor activity, identified on PET-CT
• Rapid molecular testing – subset in 3 days, full NGS panel in 10 days
• Daily tumor board – the case discussed by all specialists together, not passed from one doctor to another
• Single information system – all doctors have access to all information, zero fragmentation
• Complete diagnosis + first treatment (CyberKnife) in 10 days

What made the difference: Anadolu is a specialized oncology center – this is what they do continuously. They have concentrated experience, high case volumes, and optimized protocols. It is not a general hospital that “also does oncology.”

Leading oncology centers in Europe and Turkey

If you are evaluating options for diagnosis or second opinion, here are renowned centers with internationally recognized oncology expertise:

Turkey:

• Anadolu Medical Center, Istanbul – specialized oncology center, academic partner of Johns Hopkins (USA). Daily tumor board, AI PET-CT, rapid molecular testing.

France:

• Gustave Roussy, Paris – one of the largest oncology centers in Europe. Pioneer of rapid diagnosis (one-day breast diagnosis, since 2004).
• Institut Curie, Paris – excellence in oncology research and treatment

Germany:

• Charite Comprehensive Cancer Center, Berlin – top university center
• Heidelberg University Hospital – leader in oncology research
• University Hospital Munich (LMU) – comprehensive cancer center

Other European centers:

• Netherlands Cancer Institute (NKI), Amsterdam – cutting-edge research and treatment
• Karolinska University Hospital, Stockholm – excellence in oncology

When evaluating a center, ask: Do they have a tumor board dedicated to my cancer type? How long do molecular tests take? What generation of PET-CT do they have? Do they have an integrated information system? Also check ClinicalTrials.gov for active clinical trials in your area.

What NOT to do – summary

Here are the most common and costly mistakes you can avoid:

1. DO NOT accept a biopsy without PET-CT – you need to know the extent of the disease first
2. DO NOT start treatment without molecular testing – you may miss the treatment that suits you best
3. DO NOT accept a plan from a single doctor – ask for a tumor board
4. DO NOT settle for 21+ day wait times for tests – faster options exist
5. DO NOT make major decisions in the first 48 hours – emotions are at their peak, information is at its minimum
6. DO NOT search Google randomly – unverified information increases panic without real benefit
7. DO NOT assume your doctor does everything automatically – be your own advocate, ask, verify, request

Timeline: what is normal vs cause for concern

If your complete diagnosis takes longer than 8 weeks, actively ask what is causing the delay and whether faster options exist –including at another center.

Use AI tools as an ally in your journey

Artificial intelligence tools (ChatGPT, Claude, Gemini, and others) can be a valuable ally in your diagnostic journey. They do not replace your doctor, but they can help you:

• Understand medical terms – copy a paragraph from your pathology or imaging report and ask for an explanation in plain language
• Prepare questions for your doctor – describe your situation and ask for a list of relevant questions to bring to your next appointment
• Verify information – if you read something online and are not sure whether it is correct, ask the AI to check against NCCN or ESMO guidelines
• Understand treatment options – ask for explanations about the difference between two proposed treatments, side effects, relevant clinical trials
• Translate medical documents – if you have reports in another language, AI can translate and explain simultaneously
• Compare treatment options – check our molecular subtype guides for detailed information, then discuss with your doctor